Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tarsus Pharmaceuticals (TARS) EBITDA (2020 - 2025)

Tarsus Pharmaceuticals (TARS) has 6 years of EBITDA data on record, last reported at -$8.3 million in Q4 2025.

  • For Q4 2025, EBITDA rose 64.43% year-over-year to -$8.3 million; the TTM value through Dec 2025 reached -$66.2 million, up 42.61%, while the annual FY2025 figure was -$66.2 million, 42.61% up from the prior year.
  • EBITDA reached -$8.3 million in Q4 2025 per TARS's latest filing, up from -$12.3 million in the prior quarter.
  • Across five years, EBITDA topped out at $10.4 million in Q1 2021 and bottomed at -$41.9 million in Q4 2023.
  • Average EBITDA over 5 years is -$19.7 million, with a median of -$21.5 million recorded in 2022.
  • Peak YoY movement for EBITDA: skyrocketed 630.2% in 2021, then crashed 446.35% in 2023.
  • A 5-year view of EBITDA shows it stood at -$14.9 million in 2021, then increased by 8.0% to -$13.7 million in 2022, then crashed by 206.64% to -$41.9 million in 2023, then soared by 44.43% to -$23.3 million in 2024, then skyrocketed by 64.43% to -$8.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$8.3 million in Q4 2025, -$12.3 million in Q3 2025, and -$20.4 million in Q2 2025.